Recently, we have reported that the proportion of precursor DCs (pre-DCs) in RA peripheral blood has a strong association with treatment resistance, and their gene signature is a better predictor of response than established clinical parameters such as anti-citrullinated peptide autoantibodies (ACPA) and duration of disease (12). Here, PRTN3 is linked to rheumatoid arthritis.